Ascentage pharma to present five preclinical studies from innovative pipeline at american association of cancer research (aacr) annual meeting 2025

Rockville, md. and suzhou, china, march 25, 2025 (globe newswire) -- ascentage pharma (nasdaq: aapg; hkex: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for presentations at the 2025 american association of cancer research annual meeting (aacr), taking place april 25-30, 2025, in chicago, illinois, usa.
AAPG Ratings Summary
AAPG Quant Ranking